TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Two patients described in a MedPage Today report obtained coverage after taking denied-care disputes to insurance company leadership. Their cases show that escalation can work, but the report does not establish how often it succeeds, and advocates say patients should not have to go to such lengths for medically needed care.
Two patients whose care was initially denied obtained insurance approval after bringing their cases directly to company leadership, according to a MedPage Today report featuring stories shared by former insurance executive Wendell Potter. The cases draw attention to an escalation route some patients have used when conventional efforts to secure coverage have not succeeded, but they do not show how often contacting executives changes an insurer’s decision.
One case involved Elizabeth Nicholas, who was diagnosed with breast cancer at age 36. After months of treatment, her insurer declined to cover the type of chemotherapy her oncologist recommended. Nicholas wrote about her experience in Vanity Fair and emailed the insurer’s CEO. She later received a message from the company’s chief scientific officer stating that the treatment had been approved, according to the report. The report does not identify the insurer or provide the full details of its review.
The second patient, Donald E. Grant Jr., was 49 and had severe congenital cervical stenosis. After an earlier two-level artificial disc replacement did not adequately decompress his spinal cord, he developed myelomalacia, the report said. Grant had arranged surgery with Hyun Bae, a Cedars-Sinai spine surgeon he considered particularly qualified to treat his condition, but Bae was out of network while other parts of the operation were covered.
Grant used Claimable, an AI-assisted appeal platform, to help prepare an 11-page appeal outlining medical and legal arguments. He said in the account reported by MedPage Today that he sent it to UnitedHealth Group’s CEO and copied company leaders, lawmakers and journalists. UnitedHealthcare approved the procedure with Bae at the in-network rate. The report does not describe the company’s internal reasoning or establish that copying executives or journalists alone caused the approval.
What CEO Escalation Can Achieve
The cases show a potential route for patients facing a coverage refusal: make the case directly to senior company officials, supported by detailed medical and policy arguments. Potter, who previously worked at Cigna, told MedPage Today that large insurers have staff who handle high-profile or escalated cases and that those cases can receive special attention. That is his account of industry practice, not evidence that every insurer uses the same process or that escalation guarantees a different outcome.
The practical stakes are high when a denial affects access to a recommended treatment or to a particular specialist. But pursuing an appeal can demand time, research and knowledge of insurance rules—resources many patients may not have while managing illness. The two examples are individual cases, not a measure of success rates. Readers should not treat them as proof that an executive email will overturn a denial or replace formal appeal rights.
Potter also warned that repeated pressure from a clinician could strain the relationship with an insurer and potentially put a provider’s network status at risk. MedPage Today quoted him saying that companies can remove providers from networks. The report does not document that this happened in either patient’s case. The warning underscores why patients and clinicians may weigh escalation carefully and consider other channels, including an insurer’s medical director.
As an affiliate, we earn on qualifying purchases.
How the Two Appeals Reached Executives
The examples were highlighted by Wendell Potter in his Health Care Un-Covered newsletter. Potter told MedPage Today that cases attracting reporter attention had been elevated when he worked at Cigna. Nicholas’s experience had already been covered by Vanity Fair, while Grant’s appeal involved a detailed written submission and copies to multiple parties. The different paths mean the cases are not a controlled comparison of one escalation method.
Potter said many patients do not know how to challenge a denial. He suggested clinicians may be able to help because they understand medical needs and the healthcare system. Stephen Parente, a University of Minnesota health finance professor, told MedPage Today that a clinician could also contact an insurer’s medical director. He said a direct conversation may explain the need for care while allowing the insurer to address its concerns.
Both Potter and Parente described options for pursuing a denial, not a replacement for established review procedures. The source report does not detail the formal appeals already attempted by Nicholas or Grant, or the deadlines, policy terms and regulatory provisions that applied to their individual claims.
“You can be certain that at big insurance companies, there is a group of people around the CEO who are dedicated to high-profile cases and cases that are elevated to the C-suite or to the PR department — and they get special attention.”
— Wendell Potter, former insurance company executive, speaking to MedPage Today
What These Cases Cannot Establish
The report describes two successful cases, but does not provide data on how many patients contact executives, how many receive a reversal, or whether such appeals work better than formal insurer appeals or clinician-to-medical-director discussions. The examples therefore cannot establish that executive outreach is generally effective.
Important case details are also not fully reported, including the insurers’ original reasons for denying coverage, the complete appeal histories, and the standards used in the final reviews. The source does not say whether either patient’s approval changed a broader company policy or will affect similar claims. It also does not report that any clinician was removed from a network after escalating a case; Potter raised that as a possible risk.
Patients Still Face Appeal Decisions
The report does not identify a scheduled policy change or a formal industry response arising from the two cases. For patients who receive a denial, the next step depends on the facts of the individual claim, the insurer’s stated rationale and applicable appeal deadlines. The stories suggest that some patients may add senior leaders, a medical director, clinicians or other advocates to their efforts, but do not show which route is most likely to succeed.
Potter advised patients and clinicians not to treat an insurer’s initial “no” as necessarily final. Kemp’s criticism points to a broader policy debate over the time and effort required to secure coverage. Whether more patients will use CEO outreach—and whether insurers will change their review processes—remains unknown.
Key Questions
What happened in the two cases?
Both patients obtained coverage after taking their disputes to senior insurer officials. Nicholas received approval for the chemotherapy her oncologist recommended; Grant received approval for surgery with an out-of-network surgeon at the in-network rate.
Does emailing an insurance CEO guarantee a denial will be reversed?
No. The report presents two successful examples but provides no data on the overall results of CEO outreach or evidence that it guarantees approval.
What other escalation option did a health finance expert describe?
Stephen Parente told MedPage Today that a clinician could contact an insurer’s medical director to explain why a patient needs particular care and address the insurer’s concerns.
What risk did Wendell Potter identify?
Potter warned that frequent clinician complaints could aggravate an insurer and potentially put a provider’s network participation at risk. The report does not say that this occurred in either featured case.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
